Research studies
HIV clinical trials at OIC
Explore our HIV clinical trials and Phase I-IV research in treatment and prevention, hepatitis, vaccines, and emerging infectious diseases.
Now enrolling
3 studies are open to new participants
Gilead-5938 · Daybreak-1: Twice-Yearly HIV Treatment
Daybreak-1 compares a new, twice-yearly HIV medication combination with an already-approved option given every two months. Group 1 receives two antibody medications, teropavimab and zinlirvimab, together with the antiviral lenacapavir, dosed only twice a year. Group 2 receives cabotegravir and rilpivirine, an injectable combination already used in HIV care, given every 8 weeks. It’s for adults whose HIV is currently well controlled on a daily pill and who are interested in far less frequent dosing. Route: Group 1 takes an oral loading dose on Day 1, then receives the medication by subcutaneous injection and IV infusion; Group 2 receives intramuscular injections. Length: 92 weeks, with an optional 2-year extension phase. Compensation: $100 per completed scheduled or unscheduled visit, $300 for infusion visits. Protocol: GS-US-536-5938 (Daybreak-1) · Phase 3 · Sponsor: Gilead Sciences
I’m interested →Gilead-6544 · Daybreak-2: Twice-Yearly HIV Treatment
Daybreak-2 is a companion study to Daybreak-1, exploring the same twice-yearly medication combination for people whose HIV is already well controlled on a stable daily pill. Group 1 switches to teropavimab and zinlirvimab plus lenacapavir, dosed only twice a year. Group 2 continues on its current stable oral regimen. It’s for adults interested in trying a far less frequent dosing schedule while researchers gather more safety and effectiveness information. Route: Group 1 takes an oral loading dose on Day 1, then receives the medication by subcutaneous injection and IV infusion; Group 2 continues its stable baseline regimen. Length: 92 weeks. Compensation details are provided during screening. Protocol: GS-US-536-6544 (Daybreak-2) · Phase 3 · Sponsor: Gilead Sciences
I’m interested →Gilead-6557 · Pulsar-2: HIV Treatment for Newly Diagnosed Adults
Pulsar-2 is for adults who are newly diagnosed with HIV and haven’t yet started treatment. The study compares an investigational injectable regimen, GS-3242 combined with lenacapavir, with Biktarvy, a daily oral tablet (bictegravir, emtricitabine, and tenofovir alafenamide) that is a standard treatment option today. Researchers want to know whether the injectable regimen controls HIV as well as the daily pill, with less frequent dosing. Route: injectable regimen for the investigational group; daily oral tablet for the comparison group. Length: 52 weeks, with an optional 2-year extension phase. Compensation: $100 per completed scheduled or unscheduled visit, $100 per completed additional injection, $30 per completed phone call visit, and $400 for an optional PK sub-study visit on Day 1. Protocol: GS-US-643-6557 (Pulsar-2) · Phase 2/3 · Sponsor: Gilead Sciences
I’m interested →Full directory
Clinical Research